Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number
	09/756,411	1623	03162004
Notice of References Cited	APPLICANT(S)		
		Lori et	al.

U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
*	A	4,708,818 A	11/24/87	Montagnier et al.	435	005.000	
*	В	5,026,687 A	06/25/91	Yarchoan et al.	514	045.000	
*	\mathbf{C}_{-}	5,110,600 A	05/05/92	Green	424	450.000	
*	D	5,300,059 A	04/05/94	Rubinstein et al.	604	408.000	
*	E	5,521,161 A	05/28/96	Malley et al. (I)	514	045.000	
*	F	5,736,526 A	04/07/98	Malley et al. (II)	514	045.000	
*	G	5,736,527 A	04/07/98	Malley et al. (III)	514	045.000	
*	H	6,046,175 A	04/04/20	Lori et al. (I)	514	045.000	
*	I	6,093,702 A	07/25/00	Malley et al. (IV)	514	045.000	
*	J	6,194,390 B1	02/27/01	Lori et al. (II)	514	045.000	
*	K	6,093,702 A	07/25/00	Malley et al. (V)	514	045.000	

Foreign Patent Documents

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB- CLASS	
*	L	EP 0,206,497 A2	12/30/86	Europe(EPO)	Wellcome Fndtn			
*	M	W O 87/01284 A1	03/12/87	World(WO/PCT)	US Dept. Commerce			

*	R	Gao et al. (I), "Low Levels of Deoxynucleotides in Peripheral Blood
		Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type 1
		Replication,"
		Proc. National Academy Sciences USA, 90, 8925-8928 (October, 1993).

[†] Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER	DATE	page 1 of 5
L. E. Crane Scane	03/16/04	f: Reference not presently available.
		g furnished with this office action.
(See Manual	of Patent Examining	Procedure, Section 707.05(a).)

Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number
	09/756,411	1623	03162004
Notice of References Cited	APPLICANT(S)		
	L	Lori et	al.

		Other References (Including Author, Title, Date, Pertinent Pages, etc.)
*	\mathbf{S}^{\dagger}	Biochemicals/Organic Compounds for Research and Diagnostic Reagents,
		Sigma Chemical Co. (catalog), St. Louis, MO, 1992, pp. 321, 341-342.
*	T [†]	Feorino et al., "Prevention of Activation of HIV-1 by Antiviral Agents in
		OM-10.1 Cells,"
		Antiviral Chemistry & Chemotherapy, 4(1), 55-63 (1993).
*	U†	Snyder et al. (I), "Effects of Hydroxyurea and Thymidine Derivatives on
		the Uptake and Metabolism of Deoxycytidine and Arabinosylcytosine in Log
		Phase and Contact-Inhibited Human Fibroblasts,"
		Molecular Pharmacology, 28(6), 574-580 (1985); see p. 578 in particular.
*	V	Licastro et al., "Inhibition of Polymerases-α and -ß Completely Blocks
		DNA Repair Induced by UV Irradiation in Cultured Mouse Neuronal Cells,"
		Biochemical Biophysical Res. Comm., 132(3), 929-933 (Nov. 15, 1985).
*	W†	Busso et al., "Cellular Pharmacology and Anti-HIV Activity of 2',3'-
		Dideoxyguanosine,"
		AIDS Res. Human Retroviruses, 6(9), 1139-1146 (1990).
*	X	R. S. Root-Bernstein(I), "AIDS IS More Than HIV: Part I,"
		Genetic Engineering News, September 1, 1992, pp. 4-6.
*	Y	R. S. Root-Bernstein(II), "AIDS IS More Than HIV: Part II,"
	_	Genetic Engineering News, September 15, 1992, pp. 4-5.
*	\mathbf{z}	"Kaposi's Sarcoma and <i>Pneumocystis</i> Pneumonia Among Homosexual Men,"
		•
		Morbidity Mortality Weekly Rept., Vol. 30(25), Centers for Disease
		Control, July 3, 1981, pp. 305-308.

[†] Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

1		,
EXAMINER // //	DATE	page 2 of 5
L. E. Crane		¥: Reference not presently available.
		ng furnished with this office action. g Procedure, Section 707.05(a).)

Form PTO-892 U.S. Department of Commerce	Serial Number		Attachment to Paper Number
	09/756,411	1623	03162004
Notice of References Cited	APPLICANT(S)		
indice of Motorollous Cive		Lori et	al.

		Other References (Including Author, Title, Date, Pertinent Pages, etc.)					
*	RA†	Barre-Sinoussi et al., "Isolation of a T-Lymphotropic Retrovirus from a					
		Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS),"					
		Science, 220, 868-871 (1983).					
*	SA	Fauci (I), "The Human Immunodeficiency Virus: Infectivity and					
	-	Mechanisms of Pathogenesis,"					
		Science, 239, 617-622 (February 1988).					
*	TA	Fauci (II), "Multifactoral Nature of Human Immunodeficiency Virus					
		Disease: Implications for Therapy,"					
	0	Science, 262, 1011-1018 (November 12, 1993).					
*	UA	Zack et al., "HIV-1 Entry into Quiescent Primary Lymphocytes: Molecular					
		Analysis Reveals a Labile, Latent Viral Structure,"					
-		Cell, 61, 213-222 (April 20, 1990).					
*	VA	Bukrinsky et al., "Quiescent T Lymphocytes as an Inducible Virus					
		Reservoir in HIV-1 Infection,"					
		Science, 254, 233-237 (October 18, 1991).					
*	WA	Schnittman et al., "The Reservoir for HIV-1 in Human Peripheral Blood Is					
	i	a T Cell that Maintains Expression of CD4,"					
		Science, 245, 305-308 (July, 1989).					
*	XA	Fox et al., "Lymphoid Germinal Centers Are Resevoirs of Human					
		Immunodeficiency Virus Type 1 RNA,"					
		Journal of Infectious Diseases, 164, 1051-1057 (December, 1991).					
*	YA	Hirsch et al., "Therapy for Human Immunodeficiency Virus Infection,"					
		New England Journal of Medicine, 328(23), 1686-1695 (June 10, 1993).					

[†] Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER	DATE	page 3 of 5
L. E. Crane Man	03/16/04	¥: Reference not presently available.
		ng furnished with this office action. g Procedure, Section 707.05(a).)

Form PTO-892 U.S. Department of Commerce	Serial Number	Group Art Unit	Attachment to Paper Number
	09/756,411	1623	03162004
Notice of References Cited	APPLICANT(S)		
		Lori et	al.

		Other References (including Author, Title, Date, Fertilient Fages, etc.)			
*	ZA†	Pauwels et al., "Rapid and Automated Tetrazolium-Based Colorimetric			
		Assay for the Detection of Anti-HIV Compounds,"			
		Journal of Virological Methods, 20, 309-321 (1988).			
*	RB	Yarchoan et al., "Clinical Pharmacology of 3'-Azido-2', 3'-			
		dideoxythymidine (Zidovudine) and Related Dideoxynucleosides,"			
		New England Journal of Medicine, 321(11), 726-738 (September 14, 1989).			
*	SB [†]	Chow et al., "Use of Evolutionary Limitations of HIV-1 Multidrug			
		Resistance to Optimize Therapy,"			
	*	Nature, 361, 650-654 (1993).			
*	TB	Lori et al.(III), "Hydroxyurea as an Inhibitor of Human Immunodeficiency			
	-	Virus-Type 1 Replication,"			
		Science, 266, 801-805 (November 4, 1994).			
*	UB†	Karlsson et al., "Hydroxyurea Increases the Phosphorylation of 3'-			
		fluorothymidine and 3'-Azidothymidine in CEM Cells,"			
		European Journal of Biochemistry, 186, 689-694 (1989).			
*	VB [†]	Marquez et al., "Acid-Stable 2'-Fluoro Purine Dideoxynucleosides as			
		Active Agents Against HIV,"			
		Journal of Medicinal Chemistry, 33(3), 978-985 (1990).			
*	w _B †	Snyder et al. (II), "The Accumulation of DNA Breaks Due to Incision;			
	0.	Comparative Studies with Various Inhibitors," Ch. 2 in DNA Repaiet al. r and			
		Its Inhibition, Nucleic Acids Symposium Series No. 13, Collins et al. eds., IRL			
		Press, Oxford, England, 1984, pp. 13-33.			
		filess, Oktore, England, 1904, pp. 13-33.			

[†] Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER 111		page 4 of 5				
L. E. Crane A Cean	03/16/04	¥: Reference not presently available.				
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)						

Form PTO-892 U.S. Department of Commerce	Serial Number	-	Attachment to Paper Number
	09/756,411	1623	03162004
Notice of References Cited	APPLICANT(S)		
		Lori et	al.

_		Other References (including Author, Title, Date, Pertinent Pages, etc.)			
*	ХВ	Vila et al., "Absence of Viral Rebound After Treatment of HIV-Infected Patients with Didanosine [ddI] and Hydroxycarbamide [aka Hydroxyurea]," Lancet, 350(9078), 635-636 (August 30, 1997).			
*	YB				
		The New York Times Magazine, pp. 32-35, June 21, 1998.			
*	ZB [†]	Balzarini, J., "Effect of Antimetabolite Drugs of Nucleotide Metabolism on			
		the Anti-Human Immunodeficiency Virus Activity of Nucleoside Reverse			
		Transcriptase Inhibitors,"			
		Pharmacology and Therapeutics, 87(2-3), 175-187 (2000).††			
*	\mathbf{RC}^{\dagger}	Gao et al. (II), "Enhancement by Hydroxyurea of the Anti-Human			
		Immunodeficiency Virus Type 1 Potency of 2'-β-Fluoro-2',3'-			
		dideoxyadenosine in Peripheral Blood Mononuclear Cells,"			
		Biochemical Pharmacology, 50(2), 274-276 (1995).††			
*	\mathbf{SC}^{\dagger}	Masood et al., "2'-Fluoro-2',3'-dideoxyarabinosyladenine: A Metabolically			
		Stable Analogue of the Antiretroviral Agent 2',3'-Dideoxyadenosine,"			
Щ		Molecular Pharmacology, 37, 590-596 (1990).			
	\mathbf{TC}^{\dagger}	Hitchcock et al., "Biochemical Pharmacology of 2'-Fluoro-2',3'-			
		dideoxyarabinosyladenine, an Inhibitor of HIV with Improved Metabolic and			
		Chemical Stability over 2',3'-Dideoxyadenosine,"			
		Antiviral Chemistry & Chemotherapy, 1, 319-327 (1990).			
*	UC	Gao et al. (III), "Differential Phosphorylation of Azidothymidine,			
		Dideoxycytidine, and Dideoxyinosine in Resting and Activated Peripheral			
		Blood Mononuclear Cells,"			
		Journal of Clinical Investigations, 91(5), 2326-2333 (May, 1993).			

[†] Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Copy kindly supplied by Applicant.

	EXAMINER ///	DATE	page 5 of 5			
	L. E. Crane (Can	03/16/04	¥: Reference not presently available.			
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)						